Lung cancer highlights from ASCO 2005

Ornella Belvedere, Francesco Grossi

Research output: Contribution to journalArticle

Abstract

Exciting news regarding lung cancer was presented at the American Society of Clinical Oncology (ASCO) 2005 Annual Meeting held in Orlando, FL. Last but not least among the big killers, after breast cancer and colorectal cancer, non-small cell lung cancer (NSCLC) can now benefit from the addition of a molecularly targeted agent to standard first-line chemotherapy. The Eastern Cooperative Oncology Group 4599 phase III trial showed superior survival in patients with advanced nonsquamous NSCLC when the angiogenesis inhibitor bevacizumab was added to standard firstline chemotherapy with carboplatin and paclitaxel, compared with the same chemotherapy alone. Careful patient selection is mandatory to avoid fatal bleeding following bevacizumab administration. The role of surgery in the multimodality treatment of stage III NSCLC was further defined by the North American Intergroup 0139 trial and the European Organization for the Research and Treatment of Cancer Lung Cancer group 08941 trial. The final results of the Adjuvant Navelbine International Trialist Association trial add further support to adjuvant platinum-based chemotherapy following radical surgery in early-stage NSCLC. Interesting studies further addressed the correlation between molecular tumor profiling and clinical outcome with molecularly targeted agents in NSCLC, in particular gefitinib and erlotinib. Still, the Southwest Oncology Group 0023 randomized trial of maintenance gefitinib after definitive chemoradiation in unresectable NSCLC failed to demonstrate an advantage for maintenance gefitinib over placebo. Unfortunately, no striking results have been reported for small cell lung cancer and pleural malignant mesothelioma. The results of the studies in this report are updated with the data presented at the 2005 ASCO Annual Meeting.

Original languageEnglish
Pages (from-to)39-50
Number of pages12
JournalThe oncologist
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Medical Oncology
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Drug Therapy
Maintenance
Angiogenesis Inhibitors
Carboplatin
Small Cell Lung Carcinoma
Paclitaxel
Platinum
Patient Selection
Colorectal Neoplasms
Placebos
Breast Neoplasms
Hemorrhage
Survival
Therapeutics
Research
gefitinib
Neoplasms

Keywords

  • Adjuvant chemotherapy
  • Advanced disease
  • Elderly
  • Locally advanced disease
  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Lung cancer highlights from ASCO 2005. / Belvedere, Ornella; Grossi, Francesco.

In: The oncologist, Vol. 11, No. 1, 01.2006, p. 39-50.

Research output: Contribution to journalArticle

Belvedere, Ornella ; Grossi, Francesco. / Lung cancer highlights from ASCO 2005. In: The oncologist. 2006 ; Vol. 11, No. 1. pp. 39-50.
@article{c68def3f95c543f3ac10fe6cc533a18a,
title = "Lung cancer highlights from ASCO 2005",
abstract = "Exciting news regarding lung cancer was presented at the American Society of Clinical Oncology (ASCO) 2005 Annual Meeting held in Orlando, FL. Last but not least among the big killers, after breast cancer and colorectal cancer, non-small cell lung cancer (NSCLC) can now benefit from the addition of a molecularly targeted agent to standard first-line chemotherapy. The Eastern Cooperative Oncology Group 4599 phase III trial showed superior survival in patients with advanced nonsquamous NSCLC when the angiogenesis inhibitor bevacizumab was added to standard firstline chemotherapy with carboplatin and paclitaxel, compared with the same chemotherapy alone. Careful patient selection is mandatory to avoid fatal bleeding following bevacizumab administration. The role of surgery in the multimodality treatment of stage III NSCLC was further defined by the North American Intergroup 0139 trial and the European Organization for the Research and Treatment of Cancer Lung Cancer group 08941 trial. The final results of the Adjuvant Navelbine International Trialist Association trial add further support to adjuvant platinum-based chemotherapy following radical surgery in early-stage NSCLC. Interesting studies further addressed the correlation between molecular tumor profiling and clinical outcome with molecularly targeted agents in NSCLC, in particular gefitinib and erlotinib. Still, the Southwest Oncology Group 0023 randomized trial of maintenance gefitinib after definitive chemoradiation in unresectable NSCLC failed to demonstrate an advantage for maintenance gefitinib over placebo. Unfortunately, no striking results have been reported for small cell lung cancer and pleural malignant mesothelioma. The results of the studies in this report are updated with the data presented at the 2005 ASCO Annual Meeting.",
keywords = "Adjuvant chemotherapy, Advanced disease, Elderly, Locally advanced disease, Neoadjuvant chemotherapy, Non-small cell lung cancer",
author = "Ornella Belvedere and Francesco Grossi",
year = "2006",
month = "1",
doi = "10.1634/theoncologist.11-1-39",
language = "English",
volume = "11",
pages = "39--50",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "1",

}

TY - JOUR

T1 - Lung cancer highlights from ASCO 2005

AU - Belvedere, Ornella

AU - Grossi, Francesco

PY - 2006/1

Y1 - 2006/1

N2 - Exciting news regarding lung cancer was presented at the American Society of Clinical Oncology (ASCO) 2005 Annual Meeting held in Orlando, FL. Last but not least among the big killers, after breast cancer and colorectal cancer, non-small cell lung cancer (NSCLC) can now benefit from the addition of a molecularly targeted agent to standard first-line chemotherapy. The Eastern Cooperative Oncology Group 4599 phase III trial showed superior survival in patients with advanced nonsquamous NSCLC when the angiogenesis inhibitor bevacizumab was added to standard firstline chemotherapy with carboplatin and paclitaxel, compared with the same chemotherapy alone. Careful patient selection is mandatory to avoid fatal bleeding following bevacizumab administration. The role of surgery in the multimodality treatment of stage III NSCLC was further defined by the North American Intergroup 0139 trial and the European Organization for the Research and Treatment of Cancer Lung Cancer group 08941 trial. The final results of the Adjuvant Navelbine International Trialist Association trial add further support to adjuvant platinum-based chemotherapy following radical surgery in early-stage NSCLC. Interesting studies further addressed the correlation between molecular tumor profiling and clinical outcome with molecularly targeted agents in NSCLC, in particular gefitinib and erlotinib. Still, the Southwest Oncology Group 0023 randomized trial of maintenance gefitinib after definitive chemoradiation in unresectable NSCLC failed to demonstrate an advantage for maintenance gefitinib over placebo. Unfortunately, no striking results have been reported for small cell lung cancer and pleural malignant mesothelioma. The results of the studies in this report are updated with the data presented at the 2005 ASCO Annual Meeting.

AB - Exciting news regarding lung cancer was presented at the American Society of Clinical Oncology (ASCO) 2005 Annual Meeting held in Orlando, FL. Last but not least among the big killers, after breast cancer and colorectal cancer, non-small cell lung cancer (NSCLC) can now benefit from the addition of a molecularly targeted agent to standard first-line chemotherapy. The Eastern Cooperative Oncology Group 4599 phase III trial showed superior survival in patients with advanced nonsquamous NSCLC when the angiogenesis inhibitor bevacizumab was added to standard firstline chemotherapy with carboplatin and paclitaxel, compared with the same chemotherapy alone. Careful patient selection is mandatory to avoid fatal bleeding following bevacizumab administration. The role of surgery in the multimodality treatment of stage III NSCLC was further defined by the North American Intergroup 0139 trial and the European Organization for the Research and Treatment of Cancer Lung Cancer group 08941 trial. The final results of the Adjuvant Navelbine International Trialist Association trial add further support to adjuvant platinum-based chemotherapy following radical surgery in early-stage NSCLC. Interesting studies further addressed the correlation between molecular tumor profiling and clinical outcome with molecularly targeted agents in NSCLC, in particular gefitinib and erlotinib. Still, the Southwest Oncology Group 0023 randomized trial of maintenance gefitinib after definitive chemoradiation in unresectable NSCLC failed to demonstrate an advantage for maintenance gefitinib over placebo. Unfortunately, no striking results have been reported for small cell lung cancer and pleural malignant mesothelioma. The results of the studies in this report are updated with the data presented at the 2005 ASCO Annual Meeting.

KW - Adjuvant chemotherapy

KW - Advanced disease

KW - Elderly

KW - Locally advanced disease

KW - Neoadjuvant chemotherapy

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=31444456587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444456587&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.11-1-39

DO - 10.1634/theoncologist.11-1-39

M3 - Article

C2 - 16401712

AN - SCOPUS:31444456587

VL - 11

SP - 39

EP - 50

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -